Nausea and Vomiting Clinical Trial
Official title:
Impact of Ultrasound-Guided Transversus Abdominis Plane Block on Postoperative Nausea and Vomiting and Early Outcome After Laparoscopic Bariatric Surgery: a Randomized Double-Blinded Controlled Trial
Purpose: To explore and compare Ultrasound-Guided Transversus Abdominis Plane Block on Postoperative nausea and vomiting and Early Outcome After Laparoscopic Bariatric Surgery To evaluate and examine TAPB can reduce the application of intraoperative and postoperative opioids and the duration of analgesia
Poor postoperative nausea and vomiting control is a leading factor that hinders the physical rehabilitation, and causes acute cognitive impairment and chronic pain syndrome. Recently, the multimodal analgesia strategies to minimise opioid-related side effects are highly desirable in open surgical procedures. The transversus abdominis plane block is a novel technique involving injection of local anaesthetic between the internal oblique and the transversus abdominis muscles of the abdominal wall. Although ropivacaine is most commonly used for this technique, the analgesic duration remains not dissatisfied. Herein, we will evaluate the efficacy of ultrasound-guided transversus abdominis plane (USG-TAP) block with ropivacaine in Laparoscopic Bariatric Surgery ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
| Withdrawn |
NCT00891761 -
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
| Completed |
NCT05533281 -
Efficacy of Three Antiemetics in Preventing Nausea and Vomiting
|
Phase 4 | |
| Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
| Completed |
NCT00293384 -
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
|
N/A | |
| Completed |
NCT00006348 -
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
|
Phase 3 | |
| Completed |
NCT00004895 -
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT00003817 -
Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT06045364 -
Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation
|
Phase 1/Phase 2 | |
| Completed |
NCT00978185 -
Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy
|
Phase 3 | |
| Completed |
NCT00064272 -
UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
|
Phase 2 | |
| Completed |
NCT00003213 -
Drugs to Reduce the Side Effects of Chemotherapy
|
Phase 3 | |
| Recruiting |
NCT05690802 -
The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
|
N/A | |
| Recruiting |
NCT06314906 -
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
|
Phase 3 | |
| Completed |
NCT00590317 -
Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
|
Phase 2 | |
| Completed |
NCT03185156 -
The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate
|
Phase 4 | |
| Not yet recruiting |
NCT06382012 -
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
|
Phase 2/Phase 3 | |
| Terminated |
NCT01275664 -
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
|
N/A | |
| Completed |
NCT01590147 -
Supportive Intervention Programs Study
|
N/A | |
| Completed |
NCT00381862 -
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
|
Phase 2 |